Journal article
IL-6-driven STAT signalling in circulating CD4 lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis
AE Anderson, AG Pratt, MAK Sedhom, JP Doran, C Routledge, B Hargreaves, PM Brown, KA Lê Cao, JD Isaacs, R Thomas
Annals of the Rheumatic Diseases | BMJ PUBLISHING GROUP | Published : 2016
Open access
Abstract
Objectives: A previously identified signal transduction and activator of transcription-3 (STAT3) target-enriched gene signature in circulating CD4+ T cells of patients with early rheumatoid arthritis (RA) was prominent in autoantibody-negative individuals. Here, interleukin (IL)-6-mediated STAT signalling was investigated in circulating lymphocytes of an independent early arthritis patient cohort, seeking further insight into RA pathogenesis and biomarkers of potential clinical utility. Methods: Constitutive and IL-6-induced expression of phosphorylated STAT1 (pSTAT1) and pSTAT3 was determined in T and B cells using Phosflow cytometric analysis in patients with RA and controls. Contemporaneo..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
Pfizer, the Academy of Medical Sciences, NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals Foundation Trust & Newcastle University; NHMRC grants 1027657 and 569938; ARC Future Fellowship. The views expressed are those of the authors and not necessarily those of Pfizer, the NHS, the NIHR or the Department of Health.